Form D · Biotechnology
Alume Biosciences Inc
La Jolla, CA · CIK 0001782348
Offering snapshot reported May 8, 2026 · SEC filing
- Reported sold
- $2.16M Offering amount: $8M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Mar 24, 2026 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$110,000 → $2,160,000
- Reported investors2 → 4
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2026 | Amendment | $2,160,000 | $2,050,000vs Apr 6, 2026 | 4 | SEC filing |
| Apr 6, 2026 | Initial | $110,000 | No comparison | 2 | SEC filing |
| Feb 19, 2026 | Amendment | $6,853,305 | $886,000vs Jan 30, 2026 | 92 | SEC filing |
| Jan 30, 2026 | Amendment | $5,967,305 | No comparison | 77 | SEC filing |
| Dec 31, 2025 | Amendment | $5,316,105 | $1,704,989vs Nov 12, 2025 | 62 | SEC filing |
| Nov 12, 2025 | Amendment | $3,611,116 | $555,616vs Oct 31, 2025 | 46 | SEC filing |
| Oct 31, 2025 | Initial | $3,055,500 | No comparison | 37 | SEC filing |
| Jan 9, 2023 | Initial | $12,759,950 | No comparison | 43 | SEC filing |
| Sep 21, 2022 | Amendment | $4,000,000 | $950,000vs Apr 15, 2022 | 26 | SEC filing |
| Apr 15, 2022 | Initial | $3,050,000 | No comparison | 23 | SEC filing |
| Aug 26, 2020 | Initial | $4,000,000 | No comparison | 34 | SEC filing |
| Jul 11, 2019 | Initial | $5,772,023 | No comparison | 40 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-579251
Simple Agreement for Future Equity
Source: Form D, filed May 8, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brett Berman | Director, Executive |
| Dan Bradbury | Director |
| Kim Kamdar | Director |
| Magda Marquet | Director |
| Jean Pierre Million | Director |
| Jean Pierre Millon | Director |
| Quyen Nguyen | Director, Executive |
| Kaveri Parker | Executive |
| James Schmidt | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2223 Avenida De La Playa Suite 205
La Jolla, CA, 92037
La Jolla, CA, 92037